Search results
Showing 46 to 60 of 100 results for bladder cancer
NG2/3 Question In people with high-risk non-muscle-invasive bladder cancer, are these follow-up regimens equally effective in terms of...
Awaiting development [GID-TA11592] Expected publication date: TBC
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued [GID-TA10394]
Awaiting development [GID-TA10967] Expected publication date: TBC
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
Microwave ablation for primary or metastatic cancer in the lung (IPG716)
Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).
View recommendations for IPG716Show all sections
High dose rate brachytherapy for carcinoma of the cervix (IPG160)
Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.
View recommendations for IPG160Show all sections
Sections for IPG160
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
Laparoscopic prostatectomy for benign prostatic obstruction (IPG275)
Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).
View recommendations for IPG275Show all sections
Sections for IPG275
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG756)
Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.
View recommendations for IPG756Show all sections
Evidence-based recommendations on low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer in adults. This involves using an X-ray tube inserted into the rectum to destroy the cancer cells.
View recommendations for IPG659Show all sections